Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegenerative Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Cystatin B (CSTB) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSTB Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified, Theoretical MW confirmed. Suitable for protease inhibition assays. |
View CSTB Products |
| Gene Delivery | CSTB Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View CSTB Products |
| Benchmark Ab | Anti-CSTB Recombinant Antibody Sequence-verified positive control for ELISA, Western Blot, and IHC. |
View CSTB Products |
| Validator | CSTB siRNA Set For target knockdown validation in functional cell-based assays. |
View CSTB Products |
| Related Target A | CTSB (Cathepsin B) Primary intracellular target inhibited by CSTB; key in lysosomal pathway and cancer invasion. |
View CTSB Products |
| Related Target B | CST3 (Cystatin C) Homologous extracellular cystatin; critical for off-target selectivity screening. |
View CST3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over homologues (e.g., Cystatin C) | High-purity recombinant CST3 and CSTB panels available for comparative SPR/ELISA screening. |
| Assay reproducibility in protease inhibition | Strictly controlled batch-to-batch consistency with verified theoretical molecular weight and sequence integrity. |
| Lack of Controls | Clinical-grade benchmark antibodies included as positive controls. |
| False Positives in phenotypic screens | Sequence-verified siRNA included for target-specific knockdown verification. |
Live Cystatin B/CSTB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cystatin B (CSTB) is gaining momentum as its biological roles in oncology and neurodegeneration become clearer. Traditionally known for its loss-of-function mutation in Progressive Myoclonus Epilepsy Type 1A (EPM1A), CSTB is increasingly recognized as an overexpressed biomarker and therapeutic target in multiple solid tumors, including gliomas, lung, and ovarian cancers. In these oncological contexts, CSTB acts as an inhibitor of cathepsin-induced apoptosis, promoting tumor cell survival and metastasis.
"The race for CSTB therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted monoclonal antibodies and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting CSTB-cathepsin protein-protein interactions (PPI) to selectively restore apoptotic pathways in cancer cells."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Institutes, Biotech Startups | Glioma, Solid Tumors | High-purity CSTB and CTSB (Cathepsin B) proteins for robust in vitro binding and inhibition assays. |
| Monoclonal Antibodies (mAbs) | Biopharma Innovators | Metastatic Cancers, Neuroinflammation | Sequence-verified CSTB extracellular domain/full-length proteins for epitope mapping and affinity determination. |
| Gene Therapy (AAV-mediated) | Orphan Drug Developers | Progressive Myoclonus Epilepsy (EPM1A) | Lentivirus/ORF constructs for stable expression and in vitro functional rescue validation. |